22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Treatment strategies for the right heart in pulmonary hypertension

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The function of the right ventricle (RV) determines the prognosis of patients with pulmonary hypertension. While much progress has been made in the treatment of pulmonary hypertension, therapies for the RV are less well established. In this review of treatment strategies for the RV, first we focus on ways to reduce wall stress since this is the main determinant of changes to the ventricle. Secondly, we discuss treatment strategies targeting the detrimental consequences of increased RV wall stress. To reduce wall stress, afterload reduction is the essential. Additionally, preload to the ventricle can be reduced by diuretics, by atrial septostomy, and potentially by mechanical ventricular support. Secondary to ventricular wall stress, left-to-right asynchrony, altered myocardial energy metabolism, and neurohumoral activation will occur. These may be targeted by optimising RV contraction with pacing, by iron supplement, by angiogenesis and improving mitochondrial function, and by neurohumoral modulation, respectively. We conclude that several treatment strategies for the right heart are available; however, evidence is still limited and further research is needed before clinical application can be recommended.

          Related collections

          Most cited references91

          • Record: found
          • Abstract: found
          • Article: not found

          Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

          To characterize mortality in persons diagnosed with primary pulmonary hypertension and to investigate factors associated with survival. Registry with prospective follow-up. Thirty-two clinical centers in the United States participating in the Patient Registry for the Characterization of Primary Pulmonary Hypertension supported by the National Heart, Lung, and Blood Institute. Patients (194) diagnosed at clinical centers between 1 July 1981 and 31 December 1985 and followed through 8 August 1988. At diagnosis, measurements of hemodynamic variables, pulmonary function, and gas exchange variables were taken in addition to information on demographic variables, medical history, and life-style. Patients were followed for survival at 6-month intervals. The estimated median survival of these patients was 2.8 years (95% Cl, 1.9 to 3.7 years). Estimated single-year survival rates were as follows: at 1 year, 68% (Cl, 61% to 75%); at 3 years, 48% (Cl, 41% to 55%); and at 5 years, 34% (Cl, 24% to 44%). Variables associated with poor survival included a New York Heart Association (NYHA) functional class of III or IV, presence of Raynaud phenomenon, elevated mean right atrial pressure, elevated mean pulmonary artery pressure, decreased cardiac index, and decreased diffusing capacity for carbon monoxide (DLCO). Drug therapy at entry or discharge was not associated with survival duration. Mortality was most closely associated with right ventricular hemodynamic function and can be characterized by means of an equation using three variables: mean pulmonary artery pressure, mean right atrial pressure, and cardiac index. Such an equation, once validated prospectively, could be used as an adjunct in planning treatment strategies and allocating medical resources.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Mitochondrial dynamics--mitochondrial fission and fusion in human diseases.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

              Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.
                Bookmark

                Author and article information

                Journal
                Cardiovasc Res
                Cardiovasc. Res
                cardiovascres
                Cardiovascular Research
                Oxford University Press
                0008-6363
                1755-3245
                October 2017
                05 September 2017
                05 September 2017
                : 113
                : 12 , Spotlight Issue The Right Ventricle
                : 1465-1473
                Affiliations
                [1 ]Department of Pulmonary Diseases, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands;
                [2 ]Department of Medical Biology, Academic Medical Center, Amsterdam, The Netherlands;
                [3 ]Department of Cardio-Thoracic Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands;
                [4 ]Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
                Author notes
                [* ] Corresponding author. Tel: +31 20 444 2196; fax: +31 20 444 4328, E-mail: b.westerhof@ 123456vumc.nl
                Article
                cvx148
                10.1093/cvr/cvx148
                5852547
                28957540
                7b9e71ae-8815-4356-9276-02f75be89fc7
                © The Author 2017. Published on behalf of the European Society of Cardiology

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 31 March 2017
                : 15 June 2017
                : 01 September 2017
                Page count
                Pages: 9
                Funding
                Funded by: Dutch Heart Foundation 10.13039/501100002996
                Categories
                Invited Spotlight Reviews

                Cardiovascular Medicine
                diuretics,ventricular-assist device,cardiac resynchronisation,mitochondrial function,beta-blockade

                Comments

                Comment on this article